

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: National Phase Application of PCT/GB03/00211

Applicant

: Karel DOREY et al.

Filed

: Herewith

TC/A.U.

Examiner

Docket No.

: 3198-102

Customer No.

: 06449

Confirmation No.

.

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. The publications, which are listed on the attached Form 1449, were cited in an International Search Report (copy attached herewith) in corresponding International Application No.

PCT/GB03/00211. Applicants believe that the Patent and Trademark Office should have copies of these publications from the ISA. If, however, the publications are missing from files, Applicants will provide copies, if notified.

Respectfully submitted,

Ву

effrey L. Ihnen

Attorney for Applicants

Registration No. 28,957

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005

Telephone: (202)783-6040

DT15 Pood PCT/PTO 2 0 JUL 2004 Complete. known **Application Number** National Phase Application of INFORMATION DISCLOSURE PCT/GB03/00211 STATEMENT BY APPLICANT Filing Date Herewith First Named Inventor Karel DOREY et al. **Group Art Unit Examiner Name** 2 Attorney Docket Number 3198-102 Sheet 1 of **U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Applicant **Date of Publication** of Cited Document of Cited Document Examiner Cite Kind Code² Number Initials* No.1 MM-DD-YYYY (if known) **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication of Name of Patentee or Applicant of Examiner Cite Cited Document \mathbf{Kind}^{5} Office³ Number⁴ Т° Initials* No.1 Cited Document MM-DD-YYYY Code (if known) WO 01/94408 Europe Molecular Biology Lab 12-13-2001 WO 03/031608 Α 04-17-2003 Susan Branford et al. Examiner Date

Considered

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

						MINA Panis Derema O O III	_000	
					Complete nown 2 0 JUL 200			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	National Phase Application of PCT/GB03/00211		
					Filing Date	Herewith		
					First Named Inventor	Karel DOREY et al.		
					Group Art Unit			
					Examiner Name			
Sheet 2 of 2				2	Attorney Docket Number	3198-102		
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	item (hook magazina io					of the article (when appropriate), title of the etc.), date, page(s), volume-issue number(s), there published	T ²	
		Barila, D. et al., "An Intramolecular SH3-Domain Interaction Regulates C-ABL Activity", Nature Genetics, Vol. 18, March 1998, pp. 280-282						
		Dorey, K., et al., "Regulation of Human C-Abl Tyrosine Kinase Activity in Xenopus Oocytes and Acceleration of Progesterone-Induced G2/M Transition By Oncogenic Forms", Biological Chemistry, Vol. 380, No. 2, February 1999, pp. 223-230						
		and	Dorey, Karel et al., "Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.", Oncogene, Vol. 20, No. 56, Dec. 6, 2001, pp. 8075-8084					
		Pluk	, Helma e	et al., "Autoi	nhibition of c-Ab1", Cell, Vol.	108, No. 2, Jan. 24, 2002, pp. 247-259		
		ST1	Topaly, J. et al., "Syntergistic Activity of the New ABL-Specific Tyrosine Kinase Inhibitor ST1571 and Chemotherapeutic Drugs on BCR-ABL-Positive Chronic Myelogenous Leukemia Cells", Leukemia, Vol. 15, May 2001, pp. 342-347					
Van Etten, Richard A., "Cycling, stressed-out and nervous: Cellula Trends in Cell Biology, Vol. 9, No. 5, May 1999, pp. 179-186								
Walkenhorst, Jeurgen et al., "Analysis of human c-Abl tyrosine kinase a in S. pombe.", Oncogene, Vol. 12, No. 7, 1997, pp. 1513-1520								
	Wen, S-T et al., "The PAG gene product, a stressed-induced protein with antioxidant properties, is an Ab1 SH3-binding protein and a physiological inhibitor of c-AbI tyrosine kinase activity", Genes and Development, Vol. 11, No. 19, October 1, 1997, pp. 2456-24							
Wu, J.J. et al., "Comparison of the intrinsic kinase activity and substrate specifiand Bcr-Abl" Bioorganic and Medicinal Chemistry Letters, Vol. 8, No. 17, Septempp. 2279-2284						tivity and substrate specificity of c-Abl ters, Vol. 8, No. 17, September 8, 1998,		
					·			
	_							
Examiner					 	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.